## Overall assessment

The manuscript has a defensible, bounded contribution: an inspectable ARBITER implementation plus a **single-run, complete-workflow comparison** against the same model given a minimal prompt. It does not establish that ARBITER’s interpretations are correct, that inspectability caused the agreement gains, or that it outperforms structured alternatives.

That boundary is mostly respected. The strongest remaining scientific edit is to bring a close, newly published RoB 2 conformance study into the Discussion. The most important interpretive qualification is that the primary forced-choice endpoint is a conditional preference among displayed labels, not a general accuracy estimate.

I used the requested pstack lenses as a read-only review: sharpened the contribution and its limits; traced the system and study design (“how”); checked the rationale in the current governing documents (“why”); and challenged the claims through independent literature, methods, and narrative reviews. The writing assessment follows the local clinical-research-writing guidance and Schimel’s emphasis on a distilled story, clear paragraph jobs, and reader effort. The current story contract and 22 October acceptance documents—not the older Round 16 briefs—governed interpretation. No files, analyses, or publication materials were changed.

## Highest-priority findings

1. **Explicitly discuss Choi et al. (2026), already reference 16.**
   At [manuscript lines 103–115](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:103), the manuscript reports algorithm conformance and compares prior systems, but never names Choi et al. The study directly examines RoB 2 run-to-run variability, agreement with an expert reference, and whether tool ratings follow their own signalling answers. It appears only in the broad citation group at line 41. Its design differs sharply—repeated assessments of one trial and one expert reference—so describe it as complementary prior work; **do not compare its percentages with ARBITER’s**. The full text reports the study design and measures [here](https://www.e-jebp.org/journal/view.php?number=21); the article was published online September 29, 2026 ([DOI](https://doi.org/10.63528/jebp.2026.00011)).

   **Suggested insertion after the process-check discussion at line 113:**
   > “A recent RoB 2 pilot also examined run-to-run variability and conformance between signalling answers and domain judgments, including in ROBoto2. Its repeated-assessment design used one trial and one expert reference; our benchmark instead evaluates one run per arm across 102 trials against two independent expert assessments. These designs address related but different questions.”[16]

2. **Keep the primary endpoint’s interpretation conditional and make that boundary more visible.**
   The 53/60 result is correctly described as the formal primary endpoint, and the manuscript explains the pathway at [lines 71–75 and 95](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:71). But the endpoint is a forced choice made after experts saw the published, Unassisted, and ARBITER labels. It estimates preference **among agreed choices, on arm-discordant cells, under this label-display task**. It does not establish population accuracy. This distinction is already in the governing brief and should remain prominent in the abstract and Discussion. The possibility that published labels refer to a broader or different target is acknowledged at line 59, but not tied directly to interpretation of the forced-choice result.

   **Suggested wording after the primary result in the Discussion:**
   > “This endpoint measures conditional preference among the displayed labels in cells with agreed expert choices; it is not a population accuracy estimate. Published labels could also concern a broader or different result than the one targeted by the two study arms.”

   The accepted brief rules out target-matching subgroup analyses, so this is a claim-calibration point, not a request for a new analysis.

3. **Describe the main comparison consistently as a complete-workflow contrast against this specific minimal-prompt comparator.**
   Both arms received identical supplied trial documents and used the same model, but the comparator lacked RoB 2 guidance and ARBITER’s assessment skill ([lines 61–65](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:61)). The Discussion already says the contrast cannot isolate component effects or establish superiority over other structured systems (line 113). Preserve that qualification wherever the result is summarized. The benchmark supports a package-level comparison—not a rule-engine effect or a claim against best-practice structured prompting.

4. **Make the closest system precedents more specific in the novelty paragraph.**
   The manuscript fairly acknowledges RobotReviewer and ROBoto2 at [lines 39 and 113](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:39). ROBoto2 already combines PDF processing, passage retrieval, LLM answers with supporting evidence, interactive reviewer correction, and official flowchart aggregation ([full ACL paper](https://aclanthology.org/2025.emnlp-demos.2.pdf), pp. 12–14; [DOI](https://doi.org/10.18653/v1/2025.emnlp-demos.2)). RobotReviewer predates LLM systems and evaluated automated judgments and supporting-text relevance ([JAMIA article](https://doi.org/10.1093/jamia/ocv044)). So the manuscript should locate its contribution in its particular retained, source-bound assessment record and paired evaluation—not imply that evidence display, human review, or algorithm-derived ratings are new.

   RoB2-Evaluator is also a close, current comparator. The manuscript identifies its fixed guidance and independent reviewers at line 113, but omits the scale and design: seven purposive calibration trials, ten separate post-freeze trials, and a repeat assessment after one week. The preprint supports comparison of implementation and evaluation choices, not a priority claim; keep its preprint status clear ([medRxiv full-text record](https://www.medrxiv.org/content/10.64898/2026.09.22.26363693v1); [DOI](https://doi.org/10.64898/2026.09.22.26363693)).

5. **The reported process checks are carefully bounded; retain those limits.**
   The manuscript distinguishes rule conformance, source binding, and structural integrity from whether evidence supports an answer ([lines 51–53, 81, 103, 111](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:51)). That distinction is scientifically important: presence of a quotation or a valid source location is not semantic support. A closer RoB-specific citation would strengthen this point: Armijo-Olivo et al. reported irrelevant RobotReviewer supporting quotations in several domains ([PubMed record and abstract](https://pubmed.ncbi.nlm.nih.gov/32065732/); [DOI](https://doi.org/10.1002/jrsm.1398)). Liu et al. is useful as a general citation-support analogy, but it evaluates generative search rather than RoB assessment ([ACL/EMNLP record](https://aclanthology.org/2023.findings-emnlp.467/)).

6. **Resolve publication-facing placeholders if this file represents the live publication.**
   The Markdown contains unresolved fields for affiliations and author order ([line 7](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:7)), expert qualifications ([line 69](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:69)), disclosures and author approval ([line 129](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:129)), and archival data citation in the back matter. The final acceptance document also records author information, expert qualifications, declarations, and archival DOI as pending. These are material reporting gaps if they remain in the published record; I cannot determine from the workspace whether the journal version has since resolved them.

## Citation and wording audit

The citations checked for the main claims generally fit their use:

- References 2–3 support RoB 2 reliability challenges and the role of implementation instructions. References 4–5 concern the earlier instrument, and the manuscript says so.
- References 8–9 support the history of evidence-assisted systems and interactive RoB 2 review. Reference 11 supports evaluation against fresh reviewers as well as published review judgments.
- Reference 12 (Xiong et al.) and reference 23 (Li et al.) concern **RoB 1**, not RoB 2. The manuscript correctly identifies these as an earlier-instrument prompt comparison and a separate human–AI collaboration study.
- Reference 16’s metadata matches the journal record, but its direct conformance finding is not discussed. Reference 24’s metadata and preprint date match medRxiv; its small post-freeze sample and repeatability aim should be stated if the paper is used as a close comparator.
- Reference 19 supports blinded adjudication in data extraction, but not the validity of a forced-choice preference endpoint. Consider removing it from the sentence about the label-choice procedure or explicitly limit the precedent to blinded adjudication.
- Reference 18 is a methodological commentary, not an empirical validation study. The phrase “Prior studies have examined…” at line 41 would be more precise if it separated empirical studies from methodological recommendations.

**Citation worth adding:** Armijo-Olivo et al. 2020 (DOI 10.1002/jrsm.1398) is a RoB-specific source on irrelevant supporting quotations.
**Citation to retain but qualify:** Liu et al. 2023 supports the general distinction between citation presence and support, as an analogy from generative search.
**No confirmed metadata errors** were found among the focal references checked against publisher, PubMed, ACL Anthology, journal, or preprint records; this was a targeted metadata check, not a full independent audit of every bibliography entry.

## Narrative review

The governing story contract is coherent: make judgments inspectable, then show what the complete workflow’s agreement comparison does and does not establish. The Introduction and Discussion mostly follow that arc. The main reader friction is that the nearest procedural-conformance precedent is buried in a broad citation cluster, while the Discussion gives more detail to RoB2-Evaluator than to Choi et al. The Conclusion also repeats inspectability in both its first and last sentences ([lines 123–124](/home/ali/Documents/Code/arbiter-JAMIA/docs/manuscript/manuscript.md:123)); one statement could be cut so the final sentence resolves the combined contribution—inspectable records and bounded agreement—without restating the opening claim.

## Literature search and inspection

Searches were run on **October 23, 2026** in PubMed/PMC and on primary publisher or proceedings sites. Search queries included: “RoB 2 large language model risk of bias assessment 2026,” “RoB2-Evaluator Joseph Vishwanath Sisirkumar,” “Choi Swan algorithm conformance RoB 2.0,” “ROBoto2 RoB 2 evaluation,” and queries for Nyrhi, Gandhi, Xiong, RobotReviewer, and human–AI RoB assessment. I followed citation trails from the recent conformance and system papers.

Full article text was inspected for Choi et al. (journal HTML), ROBoto2 (ACL PDF), Gandhi et al. (PLOS), and Huang et al. (JMIR). Joseph et al.’s preprint was inspected through searchable full-text content; the direct full-text fetch returned 403. PubMed records or abstracts were inspected for Nyrhi, Xiong, Li, Armijo-Olivo, and RobotReviewer. I did not read all 24 cited works in full text.

## Strongest relevant sources

1. [RoB 2: a revised tool for assessing risk of bias](https://doi.org/10.1136/bmj.l4898) — instrument and decision framework.
2. [RobotReviewer evaluation](https://doi.org/10.1093/jamia/ocv044) — automated bias judgments and supporting-text evaluation.
3. [ROBOTO2 system and dataset](https://aclanthology.org/2025.emnlp-demos.2/) — closest earlier interactive evidence-assisted RoB 2 platform.
4. [Huang et al., JMIR 2025](https://doi.org/10.2196/70450) — structured RoB 2 prompting, fresh independent reviewers, and published review references.
5. [Gandhi et al., PLOS One 2026](https://doi.org/10.1371/journal.pone.0353155) — contemporary RoB 2 validation with published and masked-human assessments.
6. [Nyrhi et al., eBioMedicine 2026](https://doi.org/10.1016/j.ebiom.2026.106238) — larger multi-model RoB 2 validation using published human ratings.
7. [Choi et al., J Evid-Based Pract 2026](https://doi.org/10.63528/jebp.2026.00011) — direct precedent on variability, algorithm conformance, and expert-reference agreement.
8. [Joseph et al., RoB2-Evaluator preprint](https://doi.org/10.64898/2026.09.22.26363693) — rule-constrained RoB 2 system with post-freeze repeatability and human comparison.
9. [Armijo-Olivo et al., 2020](https://doi.org/10.1002/jrsm.1398) — RoB-specific evidence that machine-provided supporting quotations can be irrelevant.
10. [Lai et al., JMIR 2026](https://doi.org/10.2196/84915) — exploratory RoB 2 feasibility study, included in the manuscript bibliography.
11. [Xiong et al., BMJ Evidence-Based Medicine 2026](https://doi.org/10.1136/bmjebm-2025-114055) — prompt comparison for RoB 1, useful context but not a direct RoB 2 comparator.
12. [Li et al., BMC Medical Research Methodology 2026](https://doi.org/10.1186/s12874-025-02763-3) — RoB 1 human–AI collaboration study, relevant to distinguishing offline agreement from reviewer-workflow effects.
13. [Liu et al., EMNLP Findings 2023](https://doi.org/10.18653/v1/2023.findings-emnlp.467) — general framework distinguishing citation occurrence from citation support.

Broad clinical AI benchmarks and unrelated model evaluations were excluded as tangents. I also avoided ranking these studies by headline percentages: their tools, targets, datasets, references, and evaluation designs differ.
